MajidF

[MajidF @MajidFassi]

@MoHU_En Hi @MoHU_En any chance we can get a feedback from nusuk for all technical issues with their website. Thanks.

[Souhila Benali @SouhilaBenali]

Comme un psaume le jour de l'Aid.#Algérie manifestations acte 30.

[Johnson & Johnson MedTech | Heart Recovery @jjmt_heartrecov]

This year, we defined our culture with our "I am Abiomed - Patients First Commitment." This is our "why" and inspires our daily execution and grit.

[Shon Chakrabarti MD MPH @shonmd]

Don’t forget the right ventricle. Great debate and points by Dr. Lynn Morris @EastCarolina #C32019 @C3_Academy #impellaRP #waronshock

[Raj Tayal @RajTayalMD]

@jason_wollmuth @AntoniousAttall @chiragbavishiMD @agtruesdell @Pooh_Velagapudi @AGoldsweig @JDawnAbbott1 @herbaronowMD @paulcgordon1 @tanmayswadia @ajaykirtane @PinakShahMD @ekgpdx Thanks Jason! Had good success with it . Tony you always maintain have wire access & will be surprised by how many times you can get away with just 1 Perclose (just don’t fully tighten it until after you remove the balloon)!

[Chirag Bavishi MD, MPH @chiragbavishiMD]

After removing the sheath, no bleeding!

[Chirag Bavishi MD, MPH @chiragbavishiMD]

Severe LM bifurcation, diabetic, EF 35%, surgical turndown. Impella assisted LM-LAD-LCX bifurcation using #DKcrush technique. IVUS guides. The highlight of the case thought was single access! Great case with Omar Hyder. Thank you @jason_wollmuth for showing us this technique!

[Journal of Cardiac Failure @JCardFail]

The use of pulmonary artery catheter in #CardiogenicShock has decreased from 2004-2014, although its use is now associated with improved outcomes, which may reflect better selection of patients or better use of the information to guide therapies. https://t.co/GWc7tbWJPG @HFSA

[Alex Truesdell @agtruesdell]

👍Another (increasingly common “full spectrum”) #SCAI2019 live case...calcified LM bifurcation, critical AS, mild LV dysfunction, calcified PAD: #shockwave lithoplasty (access), percutaneous MCS, rotational atherectomy, DK crush, coronary imaging/PCI optimization💪...

[Seth Bilazarian, MD @DrSethdb]

#SCAI2019
@Babar_Basir presentation of #NCSI data with growing prospective data collection of AMICGS best practices using #Impella pre-PCI, RHC guidance & decreasing toxic catecholamines with improved survival & native heart recovery

[Babar Basir @Babar_Basir]

#NationalCSI results of 171 patients treated with early MCS today @SCAI #SCAI2019 published in @CCIJournal AMICS is the deadliest disease we deal with in the cath lab. STEMI mortality <2% STEMI w/ CS mortality 50% for over the past 2 decades.

[Johnson & Johnson MedTech | Heart Recovery @jjmt_heartrecov]

Hear from @BillONeillMD , @jwmoses , Dr. John Lasala and Dr. Bill Lombardi on data and best practices for treating high-risk patients: https://t.co/DejKc388rb #Impella #ProtectedPCI

[MajidF @MajidFassi]

Dr Behnam Tehrani speaking on the team- and algorithm-based management of cardiogenic shock at the Inova Heart and Vascular Institute’ https://t.co/aIRbleQYdV

[Seth Bilazarian, MD @DrSethdb]

Standardized Team-Care for Cardiogenic Shock https://t.co/Q3IC62CklM …
advancing care -> its hard work but it's worth it!
Congratulations @behnam_tehrani @agtruesdell & team at @inovaheart
great audio summary by Dr. Fuster & editorial by @TanveerRab
#ShockTeam #ShockDoc

[MajidF @MajidFassi]

#RightSideSupport #ImpellaRP

[Johnson & Johnson MedTech | Heart Recovery @jjmt_heartrecov]

Today at #ACC19 @PerwaizMeraj presented data from the #Impella RP post-approval study, which demonstrates survival benefit with the Impella RP Recover Right protocol. Read more here: https://t.co/fwfj8JcARz

[Johnson & Johnson MedTech | Heart Recovery @jjmt_heartrecov]

#Impella RP post-approval data demonstrates survival benefit with the Impella RP Recover Right protocol #ACC19 Read more here: https://t.co/fwfj8JcARz

[Mike Minogue | MA Gov Candidate @mikeminoguema]

Oh yeah...patients are not anecdotes or data. They are people and we support all our hospitals 24x7 with on site and on call support. We track these patients and identify and validate best practices. Our people put patients first and our customers know our dedication.

[Mike Minogue | MA Gov Candidate @mikeminoguema]

CGS is hard to randomize. We know. These sites tried & others did not even get IRB approval. Refuse to use Impella w/o RCT?, eliminates ECMO and D2B time and RCT shows IABP does not improve hemodynamics or outcomes. AND ABMD funding CGS RCT in Germany/Denmark-DanGer. AwareRCT?

[Mike Minogue | MA Gov Candidate @mikeminoguema]

Abiomed has conducted the most studies in the field of circulatory support. Impella is the most studied VAD in the history of the FDA. Abiomed tracks 95% of commercial patients in IQ database, in cVAD prospective study, and real-time at 40+ hospitals with Impella Connect